[go: up one dir, main page]

IL232385A - Use of the compounds halofenate or halofenic acid in the manufacture of medicaments for treating hyperuricemia in patients with gout, hyperuricemia or impaired renal function - Google Patents

Use of the compounds halofenate or halofenic acid in the manufacture of medicaments for treating hyperuricemia in patients with gout, hyperuricemia or impaired renal function

Info

Publication number
IL232385A
IL232385A IL232385A IL23238514A IL232385A IL 232385 A IL232385 A IL 232385A IL 232385 A IL232385 A IL 232385A IL 23238514 A IL23238514 A IL 23238514A IL 232385 A IL232385 A IL 232385A
Authority
IL
Israel
Prior art keywords
hyperuricemia
halofenate
gout
medicaments
patients
Prior art date
Application number
IL232385A
Other languages
Hebrew (he)
Other versions
IL232385A0 (en
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of IL232385A0 publication Critical patent/IL232385A0/en
Publication of IL232385A publication Critical patent/IL232385A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL232385A 2011-11-04 2014-04-30 Use of the compounds halofenate or halofenic acid in the manufacture of medicaments for treating hyperuricemia in patients with gout, hyperuricemia or impaired renal function IL232385A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (2)

Publication Number Publication Date
IL232385A0 IL232385A0 (en) 2014-06-30
IL232385A true IL232385A (en) 2017-10-31

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232385A IL232385A (en) 2011-11-04 2014-04-30 Use of the compounds halofenate or halofenic acid in the manufacture of medicaments for treating hyperuricemia in patients with gout, hyperuricemia or impaired renal function

Country Status (14)

Country Link
EP (1) EP2775835A4 (en)
JP (1) JP6047172B2 (en)
KR (1) KR101848122B1 (en)
CN (1) CN104066323A (en)
AU (1) AU2011380509B2 (en)
BR (1) BR112014010693A2 (en)
CA (1) CA2859689C (en)
CL (1) CL2014001156A1 (en)
IL (1) IL232385A (en)
MX (1) MX354846B (en)
NZ (1) NZ624714A (en)
SG (1) SG11201402027PA (en)
WO (1) WO2013066352A1 (en)
ZA (1) ZA201403574B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155478A1 (en) * 2012-04-13 2013-10-17 Metabolex, Inc. Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
CN104068288B (en) * 2014-07-25 2016-08-24 许伟琦 A kind of feed additive of anti-lithangiuria
CN105920022A (en) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 Anti-gout medicinal compound preparation
CN111246852A (en) * 2017-10-26 2020-06-05 大塚制药株式会社 Composition containing inositol phosphate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
BRPI0819847B1 (en) * 2007-11-27 2022-01-11 Ardea Biosciences, Inc COMPOUNDS AND COMPOSITIONS

Also Published As

Publication number Publication date
CA2859689A1 (en) 2013-05-10
MX2014005399A (en) 2015-04-08
AU2011380509B2 (en) 2016-05-19
MX354846B (en) 2018-03-22
NZ624714A (en) 2016-01-29
CA2859689C (en) 2018-05-22
KR20140123927A (en) 2014-10-23
ZA201403574B (en) 2015-11-25
EP2775835A1 (en) 2014-09-17
CL2014001156A1 (en) 2015-01-16
BR112014010693A2 (en) 2020-11-10
EP2775835A4 (en) 2015-07-29
KR101848122B1 (en) 2018-04-11
WO2013066352A1 (en) 2013-05-10
JP2014532759A (en) 2014-12-08
JP6047172B2 (en) 2016-12-21
AU2011380509A1 (en) 2014-05-29
IL232385A0 (en) 2014-06-30
SG11201402027PA (en) 2014-09-26
CN104066323A (en) 2014-09-24

Similar Documents

Publication Publication Date Title
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
ZA201403795B (en) Formulations for the treatment of diabetes
IL232251B (en) A pharmaceutical combination for use in the treatment of a diabetes type 2 patient
HK1196819A1 (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
IL232384A (en) Use of the compounds halofenate or halofenic acid for the preparation of medicaments for treatment of gout
IL223289A0 (en) Treatment of type 2 diabetes
HUS2000020I1 (en) Ciclesonide for the treatment of airway disease in horses
IL233351A (en) Use of non-glycosylated apolipoprotein a-iv for the preparation of medicaments for treatment of diabetes
IL232385A (en) Use of the compounds halofenate or halofenic acid in the manufacture of medicaments for treating hyperuricemia in patients with gout, hyperuricemia or impaired renal function
ZA201403575B (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
PL2560662T3 (en) Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
IL228891A (en) 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts for use in the treatment of cardiovascular disease
IL221747A (en) Arylfluorophosphate compounds, process for the preparation thereof and use thereof in the preparation of medicaments for treating chronic renal failure
DK2656075T3 (en) Process for optimizing the treatment of patients with biological drugs
HK1196953A1 (en) Formulations for the treatment of diabetes
SG10201609202PA (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
ZA201307614B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
GB201009893D0 (en) Electrochemical reactor for the treatment of fluids
PL391810A1 (en) New ziprasidone salts and processes for the preparation thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed